JAK2 and graft versus host disease: Combination of donor derived Tregs and ruxolitinib, a Jak2 inhibitor currently approved agent for steroid refractory GVHD (16), has been shown to exert synergistic effect to improve GVHD outcomes without interference in graft vs. leukemia effect (17).